Mantle Cell Lymphoma
From the Journals
Adding bortezomib does not improve MCL outcomes
The addition of bortezomib is a bust in patients with newly diagnosed mantle cell lymphoma.
From the Journals
In young MCL patients, optimal treatment may vary
Novel agents have produced mixed results in younger mantle cell lymphoma patients.
From the Journals
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
From the Journals
Ibrutinib plus venetoclax is active in mantle cell lymphoma
The combination appears to outperform the single agents when treating relapsed/refractory mantle cell lymphoma.
From the Journals
Time to rethink MCL treatment, trial design
Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma...
Conference Coverage
Outpatient CAR T infusions feasible using liso-cel
SALT LAKE CITY – Though most patients are admitted later, hospital stays are shorter with outpatient CAR T infusion.
From the Journals
Ibrutinib linked to invasive fungal infections
The researchers called for greater awareness of the potential for fungal infection in ibrutinib-treated patients.
From the Journals
Acalabrutinib shows less off-target activity in mantle cell lymphoma
The findings add to a growing body of evidence showing that BTK inhibition disrupts the tumor microenvironment.
From the Journals
NF-kappaB pathway could help solve resistance problem in mantle cell lymphoma
The research could set the stage for therapeutic targets to help avoid drug resistance in mantle cell treatment.
From the Journals
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
From the Journals
VcR-CVAD yields high responses, ‘excellent’ survival in MCL
The moderate-intensity induction and maintenance regimen induced good responses in both younger and older patients.